UTRECHT, The Netherlands, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS) (`Merus`, `we`, `our` or the `Company`), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced financial results for the second quarter ended June 30, 2018 and provided a corporate and clinical update. `Merus continues to make progress on the advancement of our pipeline of bispecific antibody candidates derived from our Biclonics® technology platform,` said Ton Logtenberg, Ph.D., President and Chief Executive Officer of Merus. `Our clinical trials for MCLA-128, MCLA-117 and MCLA-158 are ongoing. We plan to report data from the gastric...
|
